ICON Public (NASDAQ:ICLR) PT Raised to $349.00 at TD Cowen

ICON Public (NASDAQ:ICLR) had its price objective lifted by equities research analysts at TD Cowen from $343.00 to $349.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target indicates a potential upside of 13.20% from the company’s previous close.

A number of other brokerages have also issued reports on ICLR. Mizuho reissued a “buy” rating and set a $346.00 target price on shares of ICON Public in a research note on Thursday, April 4th. Robert W. Baird raised their price target on shares of ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a report on Friday. Barclays raised their price target on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Truist Financial raised their price target on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Finally, Evercore ISI raised their price target on shares of ICON Public from $325.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $321.64.

ICON Public Trading Up 2.7 %

Shares of NASDAQ:ICLR opened at $308.31 on Friday. The firm has a fifty day moving average of $318.89 and a two-hundred day moving average of $283.09. The firm has a market capitalization of $25.44 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 1.42 and a beta of 1.15. ICON Public has a 12-month low of $181.92 and a 12-month high of $344.77. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, equities analysts expect that ICON Public will post 14.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ICLR. GAMMA Investing LLC increased its holdings in shares of ICON Public by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after purchasing an additional 32 shares during the period. Pinnacle Bancorp Inc. increased its holdings in shares of ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after purchasing an additional 55 shares during the period. Steph & Co. increased its holdings in shares of ICON Public by 4.6% during the 3rd quarter. Steph & Co. now owns 1,670 shares of the medical research company’s stock worth $411,000 after purchasing an additional 73 shares during the period. Bruce G. Allen Investments LLC bought a new position in shares of ICON Public during the 4th quarter worth about $25,000. Finally, Riverview Trust Co bought a new position in shares of ICON Public during the 1st quarter worth about $31,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.